8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Feb 19, 2026·SEC
Bicara Therapeutics Inc. Common Stock(BCAX)Earnings, Financials & Key Ratios
BCAX•NASDAQ
$23.78
$1.3B mkt cap·Price updated May 6, 2026
AboutBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.Show more
- Revenue$0
- EBITDA-$82M-106.5%
- Net Income-$68M-30.8%
- EPS (Diluted)-1.25-25.0%
- ROE-19.14%+62.9%
- ROIC-2129.28%
- Debt/Equity0.00-50.1%
BCAX Key Insights
Bicara Therapeutics Inc. Common Stock (BCAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BCAX Price & Volume
Bicara Therapeutics Inc. Common Stock (BCAX) stock price & volume — 10-year historical chart
Loading chart...
BCAX Growth Metrics
Bicara Therapeutics Inc. Common Stock (BCAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-104.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-104.59%
Return on Capital
10 Years-30.47%
5 Years-30.47%
3 Years-30.47%
Last Year-21.4%
BCAX Recent Earnings
Bicara Therapeutics Inc. Common Stock (BCAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (33%)
Q2 2026Latest
Mar 26, 2026EPS
$0.68
Est $0.72
+5.6%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$0.67
Est $0.55
-21.8%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.50
Est $0.54
+7.4%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.68
Est $0.40
-70.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.68vs $0.72+5.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.67vs $0.55-21.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.54+7.4% | — |
| Q2 2025 | May 13, 2025 | $0.68vs $0.40-70.0% | — |
Based on last 12 quarters of dataView full earnings history →
BCAX Peer Comparison
Bicara Therapeutics Inc. Common Stock (BCAX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 ERAS | 3.09B | 10.90 | -15.80 | -36.7% | 0.12 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 | |
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare BCAX vs Peers
Bicara Therapeutics Inc. Common Stock (BCAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCAX Income Statement
Bicara Therapeutics Inc. Common Stock (BCAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 141.12M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 29.13M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 31.31M | 30.62M | 63.62M | 84.83M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 1000K |
| Operating Income | -37.66M▲ 0% | -39.89M▼ 5.9% | -82.39M▼ 106.5% | -141.12M▲ 0% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -5.93% | -106.55% | - |
| EBITDA | -37.65M | -39.87M | -82.33M | -141.01M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -5.91% | -106.5% | -103.23% |
| D&A (Non-Cash Add-back) | 10K | 19K | 56K | 109K |
| EBIT | -37.73M | -39.89M | -82.39M | -136.73M |
| Net Interest Income | -108K | 1.31M | 14.58M | 19.95M |
| Interest Income | 4K | 1.31M | 14.58M | 19.95M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income/Expense | -188K | -12.09M | 14.58M | 19.95M |
| Pretax Income | -37.84M▲ 0% | -51.98M▼ 37.4% | -67.81M▼ 30.5% | -121.17M▲ 0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 1K | 5K | 187K | 350K |
| Effective Tax Rate % | -0% | -0.01% | -0.28% | -0.29% |
| Net Income | -37.84M▲ 0% | -51.98M▼ 37.4% | -68M▼ 30.8% | -121.52M▲ 0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -37.36% | -30.8% | -104.31% |
| Net Income (Continuing) | -37.84M | -51.98M | -68M | -121.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.73▲ 0% | -1.00▼ 37.0% | -1.25▼ 25.0% | -2.23▲ 0% |
| EPS Growth % | - | -36.99% | -25% | -104.59% |
| EPS (Basic) | -0.73 | -1.00 | -1.25 | - |
| Diluted Shares Outstanding | 51.76M | 51.76M | 54.42M | 54.56M |
| Basic Shares Outstanding | 51.76M | 51.76M | 54.42M | 54.56M |
| Dividend Payout Ratio | - | - | - | - |
BCAX Balance Sheet
Bicara Therapeutics Inc. Common Stock (BCAX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 4.98M | 231.07M | 502.53M | 297.37M |
| Cash & Short-Term Investments | 4.16M | 230.44M | 489.71M | 290.17M |
| Cash Only | 4.16M | 230.44M | 489.71M | 171.67M |
| Short-Term Investments | 0 | 0 | 0 | 118.49M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 68K | 100K | 12.82M | 7.21M |
| Total Non-Current Assets | 1.72M | 2.91M | 66.66M | 127.32M |
| Property, Plant & Equipment | 636K | 815K | 845K | 2.1M |
| Fixed Asset Turnover | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 117.42M |
| Other Non-Current Assets | 1.08M | 2.09M | 6.62M | 27.89M |
| Total Assets | 6.7M▲ 0% | 233.98M▲ 3390.7% | 569.2M▲ 143.3% | 424.69M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 3390.71% | 143.26% | 370.52% |
| Total Current Liabilities | 23.9M | 15.09M | 17.99M | 21.03M |
| Accounts Payable | 5.14M | 3.19M | 4.51M | 3M |
| Days Payables Outstanding | - | - | - | - |
| Short-Term Debt | 0 | 0 | 607K | 1.09M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 9.79M | 16.93M |
| Current Ratio | 0.21x | 15.32x | 27.93x | 27.93x |
| Quick Ratio | 0.21x | 15.32x | 27.93x | 27.93x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 85K | 389K | 59.33M | 880K |
| Long-Term Debt | 0 | 0 | 0 | 880K |
| Capital Lease Obligations | 0 | 372K | 131K | 1.29M |
| Deferred Tax Liabilities | 0 | 0 | 59.2M | 59.2M |
| Other Non-Current Liabilities | 85K | 17K | 0 | 0 |
| Total Liabilities | 23.98M | 15.47M | 77.32M | 21.91M |
| Total Debt | 0 | 657K | 738K | 1.98M |
| Net Debt | -4.16M | -229.78M | -488.97M | -169.7M |
| Debt / Equity | - | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | 1.20x |
| Interest Coverage | -336.21x | - | - | - |
| Total Equity | -17.28M▲ 0% | 218.51M▲ 1364.7% | 491.88M▲ 125.1% | 402.78M▲ 0% |
| Equity Growth % | - | 1364.66% | 125.11% | 591.57% |
| Book Value per Share | -0.33 | 4.22 | 9.04 | 7.38 |
| Total Shareholders' Equity | -17.28M | 218.51M | 491.88M | 402.78M |
| Common Stock | 2K | 2K | 7K | 7K |
| Retained Earnings | -101.04M | -153.02M | -221.02M | -321.58M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -136K |
| Minority Interest | 0 | 0 | 0 | 0 |
BCAX Cash Flow Statement
Bicara Therapeutics Inc. Common Stock (BCAX) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -32.08M | -45.63M | -74.75M | -74.75M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -42.25% | -63.83% | -534.49% |
| Net Income | -37.84M | -51.98M | -68M | -121.52M |
| Depreciation & Amortization | 10K | 19K | 56K | 77K |
| Stock-Based Compensation | 810K | 1.9M | 7.4M | 10.12M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 14.06M | -77K | 3.97M |
| Working Capital Changes | 4.95M | -9.62M | -14.13M | -5.63M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 2.64M | 6.85M |
| Cash from Investing | -192K | -586K | -9K | -236.16M |
| Capital Expenditures | -192K | -586K | -71K | -82K |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 62K | 0 |
| Cash from Financing | 31.7M | 272.5M | 334.03M | 56K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 31K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 160K | 149K | 1.6M | 77K |
| Net Change in Cash | -573K▲ 0% | 226.28M▲ 39590.8% | 259.27M▲ 14.6% | -349.08M▲ 0% |
| Free Cash Flow | -32.27M▲ 0% | -46.21M▼ 43.2% | -74.82M▼ 61.9% | -113.06M▲ 0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -43.22% | -61.9% | -112.43% |
| FCF per Share | -0.62 | -0.89 | -1.37 | -1.37 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.88x | 1.10x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 1K | 0 | 0 | 0 |
BCAX Key Ratios
Bicara Therapeutics Inc. Common Stock (BCAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | -51.67% | -19.14% | -30.17% |
| Return on Invested Capital (ROIC) | - | -2129.28% | -2129.28% |
| Debt / Equity | 0.00x | 0.00x | 0.00x |
| FCF Conversion | 0.88x | 1.10x | 0.93x |
BCAX SEC Filings & Documents
Bicara Therapeutics Inc. Common Stock (BCAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCAX Frequently Asked Questions
Bicara Therapeutics Inc. Common Stock (BCAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bicara Therapeutics Inc. Common Stock (BCAX) grew revenue by 0.0% over the past year. Growth has been modest.
Bicara Therapeutics Inc. Common Stock (BCAX) reported a net loss of $121.5M for fiscal year 2024.
Dividend & Returns
Bicara Therapeutics Inc. Common Stock (BCAX) has a return on equity (ROE) of -19.1%. Negative ROE indicates the company is unprofitable.
Bicara Therapeutics Inc. Common Stock (BCAX) had negative free cash flow of $113.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More BCAX
Bicara Therapeutics Inc. Common Stock (BCAX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates